New MRI-Guided radiation aims to cut prostate cancer treatment time
NCT ID NCT05676463
First seen Mar 11, 2026 · Last updated Jun 22, 2026 · Updated 14 times
Summary
This phase 2 trial tested whether MRI-guided radiation therapy, given in fewer but higher doses, could safely treat high-risk prostate cancer while reducing side effects. The study enrolled 6 men with localized, high-risk prostate cancer who also received standard hormone therapy. The goal was to see if this approach could shorten overall treatment time compared to standard radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MRI-guided radiation therapy and antiandrogen therapy
What this could lead to
If successful, this approach could offer a shorter, more precise radiation treatment for high-risk prostate cancer with fewer side effects.
What could go wrong
This was a small, terminated phase 2 trial with only 6 participants, so results are very preliminary and may not apply to larger groups. The treatment still requires ongoing hormone therapy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.